Boniche et al., 2020 - Google Patents
Immunotherapy against systemic fungal infections based on monoclonal antibodiesBoniche et al., 2020
View HTML- Document ID
- 3287006766519744327
- Author
- Boniche C
- Rossi S
- Kischkel B
- Vieira Barbalho F
- Nogueira D’Aurea Moura Ă
- Nosanchuk J
- Travassos L
- Pelleschi Taborda C
- Publication year
- Publication venue
- Journal of Fungi
External Links
Snippet
The increasing incidence in systemic fungal infections in humans has increased focus for the development of fungal vaccines and use of monoclonal antibodies. Invasive mycoses are generally difficult to treat, as most occur in vulnerable individuals, with compromised …
- 108010045030 monoclonal antibodies 0 title abstract description 121
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boniche et al. | Immunotherapy against systemic fungal infections based on monoclonal antibodies | |
| Willems et al. | Vulvovaginal candidiasis: a current understanding and burning questions | |
| Garcia-Effron | Rezafungin—mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins | |
| Garcia Carnero et al. | Immunity and treatment of sporotrichosis | |
| McGuinness et al. | Evasion of neutrophil killing by Staphylococcus aureus | |
| Ulrich et al. | Monoclonal antibodies as tools to combat fungal infections | |
| De Bernardis et al. | Studies of immune responses in Candida vaginitis | |
| Wang-Lin et al. | Pharmacokinetic and pharmacodynamic considerations for the use of monoclonal antibodies in the treatment of bacterial infections | |
| Shukla et al. | The role of B-cells and antibodies against Candida vaccine antigens in invasive candidiasis | |
| Brescini et al. | Antifungal combinations in dermatophytes | |
| Stanford et al. | Iron assimilation during emerging infections caused by opportunistic fungi with emphasis on Mucorales and the development of antifungal resistance | |
| BR Da Silva et al. | Advances in fungal peptide vaccines | |
| Escajadillo et al. | Pharmacological targeting of pore-forming toxins as adjunctive therapy for invasive bacterial infection | |
| Aman et al. | Staphylococcal bicomponent pore-forming toxins: targets for prophylaxis and immunotherapy | |
| Ebata et al. | New era in systemic sclerosis treatment: recently approved therapeutics | |
| Rodrigues et al. | Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection | |
| Sahu et al. | Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies | |
| Suchodolski et al. | Fluconazole and lipopeptide surfactin interplay during Candida albicans plasma membrane and cell wall remodeling increases fungal immune system exposure | |
| Rosario-Colon et al. | Candida cell-surface-specific monoclonal antibodies protect mice against Candida auris invasive infection | |
| Scott et al. | Multi-valent protein hybrid pneumococcal vaccines: a strategy for the next generation of vaccines | |
| Konsoula et al. | Lomentospora prolificans: an emerging opportunistic fungal pathogen | |
| Singh et al. | Protective efficacy of anti-Hyr1p monoclonal antibody against systemic candidiasis due to multi-drug-resistant Candida auris | |
| Iosifidis et al. | Advances in the treatment of mycoses in pediatric patients | |
| Nosanchuk et al. | Antibody therapy for histoplasmosis | |
| Sousa et al. | Immunization and immunotherapy approaches against Pseudomonas aeruginosa and Burkholderia cepacia complex infections |